Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Net Income towards Common Stockholders: 2017-2025

Historic Net Income towards Common Stockholders for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to -$79.1 million.

  • Autolus Therapeutics' Net Income towards Common Stockholders rose 3.63% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 16.81%. This contributed to the annual value of -$220.7 million for FY2024, which is 5.89% down from last year.
  • Per Autolus Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$79.1 million for Q3 2025, which was down 65.11% from -$47.9 million recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$6.8 million for Q4 2021, and its period low was -$44.8 billion during Q3 2021.
  • In the last 3 years, Autolus Therapeutics' Net Income towards Common Stockholders had a median value of -$52.7 million in 2024 and averaged -$56.9 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Net Income towards Common Stockholders slumped by 84,283.07% in 2021, and later spiked by 99.90% in 2022.
  • Over the past 5 years, Autolus Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$6.8 million in 2021, then plummeted by 298.16% to -$27.0 million in 2022, then crashed by 186.04% to -$77.2 million in 2023, then skyrocketed by 64.23% to -$27.6 million in 2024, then climbed by 3.63% to -$79.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$79.1 million for Q3 2025, versus -$47.9 million for Q2 2025 and -$70.2 million for Q1 2025.